IP Library › Granted Patent US 8,975,377
Granted Patent B2
US 8,975,377 · App. 12/228,255 · Granted Mar 10, 2015

Cancer treatment using humanized antibodies that bind to EphB4

Inventors: Parkash Gill (Agoura Hills, CA); Valery Krasnoperov (South Pasadena, CA); Simon William Keen (Cambridgeshire, GB); Timothy David Jones (Cambridgeshire, GB); Francis Joseph Carr (Aberdeenshire, GB)
Assignee: Vasgene Therapeutics, Inc
C07K16/2866C07K16/30A61K2039/505C07K2317/24C07K2317/56C07K2317/565C07K2317/567
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,975,377
App. No.
12/228,255
Granted
Mar 10, 2015
Kind
B2
Abstract

In certain embodiments, this application provides humanized antibodies that bind to the EphB4 protein as well as uses of the antibodies for therapeutic purposes.

Claims (8)

1. A deimmunized antibody or antigen binding fragment thereof that binds amino acids 1-537 of SEQ ID NO:53, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:14; and the light chain variable region comprises the amino acid sequence of SEQ ID NO:18.

2. The deimmunized antibody or antigen binding fragment thereof according to claim 1 with similar or greater binding affinity to amino acids 1-537 of SEQ ID NO:53 than a mouse monoclonal antibody produced from the hybridoma ATCC#PTA-6214.

3. The deimmunized antibody or antigen binding fragment thereof according to claim 1 , wherein the deimmunized antibody or antigen binding fragment thereof is conjugated to a cytotoxic agent.

4. A pharmaceutical composition comprising the deimmunized antibody or antigen binding fragment thereof according to claim 1 .

5. A deimmunized antibody or antigen binding fragment thereof that binds amino acids 1-537 of SEQ ID NO:53, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:3 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:8.

6. The deimmunized antibody or antigen binding fragment thereof according to claim 5 with similar or greater binding affinity to amino acids 1-537 of SEQ ID NO:53 than a mouse monoclonal antibody produced from the hybridoma ATCC#PTA-11338.

7. The deimmunized antibody or antigen binding fragment thereof according to claim 5 , wherein the deimmunized antibody or antigen binding fragment thereof is conjugated to a cytotoxic agent.

8. A pharmaceutical composition comprising the deimmunized antibody or antigen binding fragment thereof according to claim 5 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2009
From: GILL, PARKASH; KRASNOPEROV, VALERY; KEEN, SIMON WILLIAM; JONES, TIMOTHY DAVID; CARR, FRANCIS JOSEPH
To: VASGENE THERAPEUTICS, INC.
Reel/Frame 022495/0147 →
Continuity (2)
Provisional Application 60964496 · Aug 13, 2007
Related Publication 20090196880A1 · Aug 6, 2009